ArticleBMC oral health2025
Effects of initial periodontal treatment on heat shock protein 90 and Interleukin-1β levels in gingival crevicular fluid of stage III periodontitis patients.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimThis study aimed to evaluate the effect of phase I periodontal therapy on interleukin-1β (IL-1β) and heat shock protein 90 (HSP90) levels in gingival crevicular fluid (GCF) of patients with stage III, grade C periodontitis. MATERIALS AND
methodsNineteen systemically and periodontally healthy individuals and nineteen patients with stage III, grade C periodontitis were enrolled. Clinical parameters including plaque index (PI), gingival index (GI), probing depth (PD), bleeding on probing (BOP), and clinical attachment level (CAL) were recorded. Three site-specific GCF samples (shallow, moderate, and deep pockets) were collected from maxillary anterior teeth of periodontitis patients. IL-1β and HSP90 levels were quantified using enzyme-linked immunosorbent assay (ELISA). Clinical measurements and GCF samples were obtained at baseline and 6 weeks after baseline following initial periodontal therapy.
resultsPeriodontal therapy significantly improved clinical parameters and reduced GCF IL-1β and HSP90 levels (p < 0.05). Baseline HSP90 levels were significantly higher in moderate and deep pockets compared with healthy controls (p < 0.05). HSP90 levels in deep pockets remained significantly higher than in shallow pockets both before and after treatment (p < 0.05). A positive correlation was found between PD and IL-1β levels in moderate pockets prior to treatment (p < 0.05), and between CAL and HSP90 levels in moderate pockets both before and after treatment (p < 0.05).
conclusionWithin the limitations of this study, GCF IL-1β and HSP90 levels were elevated in patients with stage III, grade C periodontitis compared with healthy controls, but decreased following periodontal treatment in parallel with clinical improvements. Further studies are warranted to elucidate the role of HSP90 and other heat shock proteins in periodontal disease activity and pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.